We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    GS-US-536-5816 | HIV
Previous Study | Return to List | Next Study

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04811040
Recruitment Status : Active, not recruiting
First Posted : March 23, 2021
Last Update Posted : November 8, 2022
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences

Brief Summary:
The primary objective of this study is to evaluate the safety and tolerability of a combination of the broadly neutralizing antibodies (bNAbs) teropavimab (formerly GS-5423) and zinlirvimab (formerly GS-2872) in combination with the HIV capsid inhibitor lenacapavir (LEN).

Condition or disease Intervention/treatment Phase
HIV-1 Infection Drug: Oral Lenacapavir Drug: Subcutaneous Lenacapavir Biological: Teropavimab Biological: Zinlirvimab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Clinical pharmacologist and sponsor are not masked to treatment assignment.
Primary Purpose: Treatment
Official Title: A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection
Actual Study Start Date : April 8, 2021
Actual Primary Completion Date : June 9, 2022
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Lenacapavir (LEN), Teropavimab, Zinlirvimab Dose C
Participants will begin treatment by receiving LEN Dose A + LEN Dose B + teropavimab + zinlirvimab Dose C followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + teropavimab + zinlirvimab Dose C.
Drug: Oral Lenacapavir
Tablets administered without regard to food
Other Name: GS-6207

Drug: Subcutaneous Lenacapavir
Administered in the abdomen via subcutaneous injections
Other Name: GS-6207

Biological: Teropavimab
Administered intravenously
Other Names:
  • 3BNC117-LS
  • GS-5423

Biological: Zinlirvimab
Administered intravenously
Other Names:
  • 10-1074-LS
  • GS-2872

Experimental: LEN, Teropavimab, Zinlirvimab Dose D
Participants will begin treatment by receiving LEN Dose A + LEN Dose B + teropavimab + zinlirvimab Dose D followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + teropavimab + zinlirvimab Dose D.
Drug: Oral Lenacapavir
Tablets administered without regard to food
Other Name: GS-6207

Drug: Subcutaneous Lenacapavir
Administered in the abdomen via subcutaneous injections
Other Name: GS-6207

Biological: Teropavimab
Administered intravenously
Other Names:
  • 3BNC117-LS
  • GS-5423

Biological: Zinlirvimab
Administered intravenously
Other Names:
  • 10-1074-LS
  • GS-2872




Primary Outcome Measures :
  1. Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) [ Time Frame: First dose date up to Week 26 ]

Secondary Outcome Measures :
  1. Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm [ Time Frame: Week 26 ]
  2. Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm [ Time Frame: Week 26 ]
  3. Proportion of Participants With Positive Anti-Teropavimab Antibodies [ Time Frame: Week 26 ]
  4. Proportion of Participants With Positive Anti-zinlirvimab Antibodies [ Time Frame: Week 26 ]
  5. Change from Baseline in CD4+ Cell Count at Week 26 [ Time Frame: Baseline; Week 26 ]
  6. Proportion of Participants Who Develop Treatment-Emergent Resistance to Lenacapvir (LEN), Teropavimab, and Zinlirvimab [ Time Frame: Day 1 up to Week 26 ]
  7. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) [ Time Frame: First dose date up to Week 26 ]
  8. Pharmacokinetic (PK) Parameter: AUC0-t of Teropavimab, and Zinlirvimab, and LEN [ Time Frame: Day 1 up to Week 52 ]
    AUC0-t is defined as the concentration of drug over time from time zero to time "t".

  9. PK Parameter: AUClast of Teropavimab, and Zinlirvimab, and LEN [ Time Frame: Day 1 up to Week 52 ]
    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

  10. PK Parameter: T1/2 of Teropavimab, and Zinlirvimab, and LEN [ Time Frame: Day 1 up to Week 52 ]
    T1/2 is defined as the estimate of the terminal elimination half-life of the drug.

  11. PK Parameter: Cmax of Teropavimab, and Zinlirvimab, and LEN [ Time Frame: Day 1 up to Week 52 ]
    Cmax is defined as the maximum observed concentration of drug.

  12. PK Parameter: Tmax of Teropavimab, and Zinlirvimab, and LEN [ Time Frame: Day 1 up to Week 52 ]
    Tmax is defined as the time (observed time point) of Cmax.

  13. PK Parameter: Tlast of Teropavimab, and Zinlirvimab, and LEN [ Time Frame: Day 1 up to Week 52 ]
    Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).

  14. PK Parameter: Ct of Teropavimab, and Zinlirvimab, and LEN [ Time Frame: Day 1 up to Week 52 ]
    Ct is the concentration at a particular time (t).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • On first-line antiretroviral therapy (ART) for ≥ 2 years prior to screening. A change in ART regimen ≥ 28 days prior to screening for reasons other than virologic failure (VF) (eg, tolerability, simplification, drug-drug interaction profile) is allowed
  • No documented historical resistance to the current ART regimen
  • Plasma HIV-1 RNA < 50 copies/mL at screening
  • Documented plasma HIV-1 RNA < 50 copies/mL for ≥ 18 months preceding the screening visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL). Unconfirmed virologic elevations of ≥ 50 copies/mL (transient detectable viremia, or "blip") prior to screening are acceptable.
  • Proviral phenotypic sensitivity to both teropavimab and zinlirvimab at screening by the PhenoSense mAb Assay (Monogram Biosciences) for inclusion in the Primary Cohort; sensitivity at screening by the PhenoSense mAb Assay (Monogram Biosciences) to 1 mAb, either teropavimab or zinlirvimab, within 18 months prior to enrollment for inclusion in the optional Pilot Cohort

    -- In both cohorts, teropavimab sensitivity is defined as 90% inhibitory concentration (IC90) ≤ 2 μg/mL; zinlirvimab sensitivity is defined as IC90 ≤ 2 μg/mL;

  • CD4+ count nadir ≥ 350 cells/μL
  • Screening CD4+ count ≥ 500 cells/μL
  • Availability of a fully active alternative ART regimen, in the opinion of the investigator, in the event of discontinuation of the current ART regimen with development of resistance

Key Exclusion Criteria:

  • Comorbid condition requiring ongoing immunosuppression
  • Evidence of current hepatitis B virus (HBV) infection
  • Evidence of current hepatitis C virus (HCV) infection (prior infection cleared spontaneously or with treatment is acceptable)
  • History of opportunistic infection or illness indicative of Stage 3 HIV disease

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04811040


Locations
Show Show 23 study locations
Sponsors and Collaborators
Gilead Sciences
Investigators
Layout table for investigator information
Study Director: Gilead Study Director Gilead Sciences
Additional Information:
Layout table for additonal information
Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT04811040    
Other Study ID Numbers: GS-US-536-5816
First Posted: March 23, 2021    Key Record Dates
Last Update Posted: November 8, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Infections
Communicable Diseases
Disease Attributes
Pathologic Processes
Blood-Borne Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases